Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Notes Payables (2023 - 2025)

Cresco Labs (CRLBF) has disclosed Notes Payables for 2 consecutive years, with $11.9 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Notes Payables rose 0.99% year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Dec 2024, up 0.99%, and an annual FY2024 reading of $11.9 million, up 0.99% over the prior year.
  • Notes Payables was $11.9 million for Q4 2024 at Cresco Labs, up from $11.8 million in the prior quarter.
  • Across five years, Notes Payables topped out at $11.9 million in Q4 2024 and bottomed at $11.8 million in Q4 2023.